247 related articles for article (PubMed ID: 21349801)
1. Metformin: its emerging role in oncology.
Micic D; Cvijovic G; Trajkovic V; Duntas LH; Polovina S
Hormones (Athens); 2011; 10(1):5-15. PubMed ID: 21349801
[TBL] [Abstract][Full Text] [Related]
2. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
[TBL] [Abstract][Full Text] [Related]
3. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost F
Mol Cancer Ther; 2010 May; 9(5):1092-9. PubMed ID: 20442309
[TBL] [Abstract][Full Text] [Related]
4. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E; Sinnett-Smith J; Kisfalvi K
Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets of metformin antitumor action.
Sośnicki S; Kapral M; Węglarz L
Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
[TBL] [Abstract][Full Text] [Related]
7. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
8. Metformin and cancer.
Vallianou NG; Evangelopoulos A; Kazazis C
Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
[TBL] [Abstract][Full Text] [Related]
9. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
10. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
Chomanicova N; Gazova A; Adamickova A; Valaskova S; Kyselovic J
Physiol Res; 2021 Aug; 70(4):501-508. PubMed ID: 34062070
[TBL] [Abstract][Full Text] [Related]
11. Metformin in Oncology - How Far Is Its Repurposing as an Anticancer Drug?
Pácal L; Kaňková K
Klin Onkol; 2020; 33(2):107-113. PubMed ID: 32303131
[TBL] [Abstract][Full Text] [Related]
12. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
13. LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells.
Li NS; Zou JR; Lin H; Ke R; He XL; Xiao L; Huang D; Luo L; Lv N; Luo Z
Tumour Biol; 2016 Jun; 37(6):8249-58. PubMed ID: 26718214
[TBL] [Abstract][Full Text] [Related]
14. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
Algire C; Amrein L; Bazile M; David S; Zakikhani M; Pollak M
Oncogene; 2011 Mar; 30(10):1174-82. PubMed ID: 21102522
[TBL] [Abstract][Full Text] [Related]
15. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
16. Metformin in cancer.
Mallik R; Chowdhury TA
Diabetes Res Clin Pract; 2018 Sep; 143():409-419. PubMed ID: 29807101
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
[TBL] [Abstract][Full Text] [Related]
18. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
19. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
Shaw RJ; Lamia KA; Vasquez D; Koo SH; Bardeesy N; Depinho RA; Montminy M; Cantley LC
Science; 2005 Dec; 310(5754):1642-6. PubMed ID: 16308421
[TBL] [Abstract][Full Text] [Related]
20. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
